

## **Merus Appoints Setareh van Driel Shamsili as Chief Medical Officer**

December 11, 2012 2:40 PM ET

Posted on 11 December, 2012

Setareh van Driel Shamsili has more than 22 years of experience in general medicine, internal medicine and medical oncology. For the past 13 years, she has focused on both translational and clinical cancer research. She has more than eight years of experience in the pharmaceutical industry, including drug development, R&D, medical affairs, drug safety and pharmacovigilance and holds a PhD in Neuro-Oncology from Erasmus University Rotterdam.

Prior to joining Merus, Setareh van Driel Shamsili was Global Medical Leader Oncology at Astellas Pharma Global Development.

“We are delighted about Setareh van Driel Shamsili joining our team,” said Ton Logtenberg, CEO and founder of Merus. “She brings invaluable experience in oncology drug development and the pharmaceutical industry. As our antibody platforms have matured and consistently yield lead candidates for clinical development, Setareh’s expertise will be invaluable to reach our ambitious business goals.”

“Merus is spearheading the development of next-generation antibodies that will combine improved clinical efficacy with ease of manufacturing,” added Setareh van Driel Shamsili. “The platform developed by Merus enables the oncology community to explore effective targeting of various malignant disorders using novel target antigens and or antibody combinations with more confidence. I am therefore very excited to head Merus’ preparation to enter the clinical stage and I am determined to pave the way for successful clinical development of the Biclonics™ and Oligoclomics® antibodies.”